Search form

Latest News

Quidel Receives FDA Clearance for Its Lyra(TM) Molecular PCR Assay for the Detection of Human Parainfluenza Viruses (HPIV), Types 1, 2 and 3

SAN DIEGO, CA -- (Marketwired) -- --
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its Lyra Parainfluenza Assay, a real-time PCR test for the qualitative detection and identification of human parainfluenza virus (HPIV) infections for virus types 1, 2, or 3 viral RNA extracted from nasal swab and nasopharyngeal swab specimens.

Read More »

Careers

Are you a determined, optimistic, team player? Quidel is looking for talented innovators who want to be part of revolutionizing medical diagnostics.

View Current Job Openings

Support

We appreciate your efforts to improve patient care, physician services, and laboratory efficiency. We know that you will appreciate the value that Quidel brings in delivering diagnostics that do not sacrifice accuracy or ease-of-use. Please explore this site for helpful resources and how you can contact us for further support.